• Heart Failure
  • Cardiovascular Clinical Consult
  • Adult Immunization
  • Hepatic Disease
  • Rare Disorders
  • Pediatric Immunization
  • Implementing The Topcon Ocular Telehealth Platform
  • Weight Management
  • Monkeypox
  • Guidelines
  • Men's Health
  • Psychiatry
  • Allergy
  • Nutrition
  • Women's Health
  • Cardiology
  • Substance Use
  • Pediatrics
  • Kidney Disease
  • Genetics
  • Complimentary & Alternative Medicine
  • Dermatology
  • Endocrinology
  • Oral Medicine
  • Otorhinolaryngologic Diseases
  • Pain
  • Gastrointestinal Disorders
  • Geriatrics
  • Infection
  • Musculoskeletal Disorders
  • Obesity
  • Rheumatology
  • Technology
  • Cancer
  • Nephrology
  • Anemia
  • Neurology
  • Pulmonology

ACP: DOAC Dos and Don'ts Primer with Stephan Moll, MD


ACP 2021: Dr Stephan Moll covers the basics of DOAC duration for VTE, use of anticoagulation in special populations, and perioperative use of DOACs

How do you gauge a patient's "DOAC Hate Factor" and why is it important?

In his presentation "DOAC Dos and Don'ts" at the American College of Physicians Internal Medicine Meeting 2021: Virtual Experience, Stephan Moll, MD, spoke first about dosing and duration of treatment for venous thromoboembolism (VTE) using the "new" direct oral anticoagulants (DOACs) and then reviewed the approach to anticoagulant therapy in a range of special populations, including patients with obesity, with cancer, and renal compromise. He finishes his talk with a quick review of the evidence on perioperative anticoagulation.

Quantifying the "DOAC Hate Factor," he explains, is important when discussing continuation or discontinuation of anticoagulation therapy because patient preference has to be considered here. Once you know, on a scale from 0 to 10, how much hate there is, you can ask questions and try to accommodate where it's possible.

The slide show that follows is based on Dr Moll's presentation and includes links to many of the studies he mentions.

Stephan Moll, MD is Professor of Medicine in the Department of Medicine, Division of Hematology, at the University of North Carolina School of Medicine, in Chapel Hill, NC.

Related Videos
New Research Amplifies Impact of Social Determinants of Health on Cardiometabolic Measures Over Time
Overweight and Obesity: One Expert's 3 Wishes for the Future of Patient Care
Donna H Ryan, MD Obesity Expert Highlights 2021 Research Success and Looks to 2022 and Beyond
"Obesity is a Medically Approachable Problem" and Other Lessons with Lee Kaplan, MD, PhD
Related Content
© 2024 MJH Life Sciences

All rights reserved.